According to the FDA, 2024 will be the ’breakout year’ for gene therapies. For these therapies to gain regulatory approval, it’s crucial to have robust potency assays in place, making it paramount that an effective potency design is incorporated into every drug developer’s analytical strategy.

With that in mind, the 2nd Gene Therapy Potency Summit is returning to Boston in July to support you in designing and validating robust potency assays to accelerate commercialization across a range of vector types and delivery modalities.

From case studies on phase-appropriate assay development to novel data presentations on cutting-edge HPLC and mass-spectrometry-based approaches, join us this year to meet 100+ industry-leading potency assay experts from the likes of Sarepta Therapeutics, Ultragenyx, Sanofi, Spark Therapeutics, Vertex, Sangamo Therapeutics, and many others.

If you’re working on a gene therapy potency strategy, this is the leading forum to uncover relevant CQAs, evolve your potency matrix, and meet the recent changes to regulatory demands in order to ultimately prove that your product is efficacious and to accelerate commercial approval.